Trimethylamine N-oxide (TMAO) is reported to promote the pathogenesis of atherosclerosis and be associated with cardiovascular events risk. It is unknown whether plasma TMAO is associated with plaque morphology in patients with acute myocardial infarction. We investigated the relationship between the culprit plaque morphology and plasma TMAO concentration in patients with ST-segment-elevation myocardial infarction.
A cute myocardial infarction (AMI), which results from coronary artery occlusion because of thrombosis, remains the leading cause of death and disability worldwide. 1 Pathology studies have demonstrated that plaque rupture and subsequent thrombus formation is responsible for approximately two-thirds of AMI; the remaining one-third is the result of plaque erosion. 2, 3 Previous studies have shown that the risk of cardiovascular events is significantly higher in patients with plaque rupture compared with those with plaque erosion. 4 The EROSION study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion) suggested that in patients with acute coronary syndrome presenting with plaque erosion, conservative treatment with antithrombotic therapy may be a reasonable option instead of stent implantation. 5 Therefore, it is important to differentiate between plaque rupture and plaque erosion to determine a personalized treatment strategy to improve the prognosis of patients with AMI.
Trimethylamine N-oxide (TMAO), a gut microbiotadependent metabolite derived from dietary phosphatidylcholine and choline, is reported to be atherogenic. 6 A series of cohorts have demonstrated that elevated TMAO levels are associated with an increased risk of cardiovascular disease and major adverse cardiac events in patients with either stable coronary artery disease (CAD), 7, 8 or acute coronary syndrome. 9, 10 A recent in vivo study has shown that elevated plasma TMAO level is related to plaque rupture in patients with CAD. 11 However, the association between plasma TMAO levels and the culprit lesion morphology in patients with ST-segment-elevation myocardial infarction (STEMI) has not yet been investigated.
Optical coherence tomography (OCT), a high resolution near infrared light-based intravascular imaging modality, enables accurate evaluation of plaque morphology in vivo. 12, 13 In this study, we explored the relationship between plasma TMAO concentration and the culprit lesion morphology as determined by OCT in patients with STEMI.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Population and Design
We prospectively enrolled 2 cohorts for this study. The first cohort comprised sequential patients (age ≥18 years) who presented with STEMI and underwent emergent procedures at Fuwai Hospital. The culprit lesions of these patients were evaluated using OCT before interventional procedures. STEMI was defined as continuous chest pain lasting >30 minutes, ST-segment-elevation >0.1 mV in at least 2 contiguous leads or new left bundle-branch block on the 18-lead ECG, and an elevated troponin I level.
14 Patients with cardiac shock, congestive heart failure, and a history of coronary artery bypass graft were excluded. Additionally, those with left main diseases, extremely tortuous or heavily calcified vessels, or chronic total occlusion were excluded owing to the difficulty in performing OCT. Between March 2017 and March 2018, a series of 211 eligible patients with STEMI underwent OCT and were enrolled in our study cohort. The study flow chart is displayed in Figure 1 . The second cohort examined was an independent set of 53 prospectively recruited individuals (age ≥18 years) without known cardiovascular diseases from health screens, to provide normal TMAO reference interval values. This study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Fuwai Hospital. All patients provided written informed consent.
Acquisition of OCT Image
Patients were administered 300 mg aspirin, 180 mg ticagrelor, or 600 mg clopidogrel, and 100 IU/kg heparin before the interventional procedure. Percutaneous coronary intervention was performed via radial or femoral access. Thrombus aspiration was used to reduce the thrombus burden and restore antegrade coronary flow. OCT images of the culprit lesions were acquired with the frequency domain ILUMIEN OPTIS OCT system and a dragon fly catheter (St. Jude Medical, Westford, MA) after antegrade blood flow was restored, according to the intracoronary imaging technique described previously.
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OCT Image Analysis
All OCT images were anonymously analyzed on a St Jude OCT Offline Review Workstation by 3 independent investigators
WHAT IS KNOWN
• Plaque rupture and plaque erosion are the main mechanisms leading to acute myocardial infarction.
• Recent studies showed that the risk of experiencing cardiovascular events was significantly higher in patients with plaque rupture than in those with plaque erosion.
• It is important to differentiate between plaque rupture and plaque erosion to improve the risk stratification and management of acute myocardial infarction; however, an effective biomarker for plaque morphology has not yet been established.
WHAT THE STUDY ADDS
• Receiver operating characteristic curve analysis indicated that plasma trimethylamine N-oxide could differentiate between plaque rupture and plaque erosion with an area under the receiver operating characteristic curve curve of 0.89.
• Plasma trimethylamine N-oxide has the potential to serve as a novel biomarker for plaque rupture in patients with ST-segment-elevation myocardial infarction.
blinded to the other data. Inconsistent results were consensus resolved blinded to the TMAO results. According to previously established criteria, 15 plaque rupture was identified by a disrupted fibrous cap with a clear cavity formation (Figure 2 ). Plaque erosion was identified by the presence of attached thrombus overlying an intact and visible plaque, luminal surface irregularity of the plaque in the absence of a thrombus, or attenuation of the underlying plaque by the thrombus without superficial lipid or calcification proximal or distal to the thrombus ( Figure 2 ).
Laboratory Tests
Blood samples were collected via radial or femoral access before heparinization using vacutainer tubes containing EDTA.
Samples were maintained at 4°C, processed within 3 hours, and then stored at −80°C until further analysis. Plasma levels of TMAO were quantified by stable isotope dilution highperformance liquid chromatography with on line electrospray ionization tandem mass spectrometry using an API 3200 triple quadrupole mass spectrometer (AB SCIEX, Framingham, MA) with a d9-(trimethyl)-labeled internal standard as described previously. 16 The estimated glomerular filtration rate (mL/min per 1.73 m 2 ) was calculated using the modification of Diet in Renal Disease study equation.
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Statistical Analysis
Continuous data are presented as mean±SD or median (interquartile range). The Student t test or nonparametric test was used for statistical comparisons. Categorical variables are presented as count (percent); comparisons between groups were made with the χ 2 or Fisher exact test. Logistic regression analysis was performed to determine the odds ratio and 95% CI for plaque rupture stratified according to TMAO as a continuous variable. Adjustments were made for variables including age, sex, smoking, triglycerides, history of diabetes mellitus, hypertension, hs-CRP (high-sensitivity C-reactive protein), and estimated glomerular filtration rate. Area under the receiver operating characteristic curves (ROCs), sensitivity, and specificity were calculated to evaluate the predictive ability of TMAO for plaque rupture. A 2-tailed P<0.05 was considered statistically significant. The statistical analyses were performed using SPSS software, version 25 (IBM, Armonk, NY).
RESULTS
Patients Characteristics
Of the 211 patients with STEMI who underwent OCT examination, 50 patients were excluded because of in-stent thrombosis or neoatherosclerosis (n=15), massive thrombus (n=8), or poor-imaging quality (n=27; baseline characteristics in Table I in the Data Supplement). The remaining 161 patients were suitable for plaque morphology evaluation; 77 patients had plaque rupture and 69 had plaque erosion. The baseline patient characteristics are displayed in Table 1 for the entire study cohort and categorized by plaque morphology. The mean age of the cohort was 57 years, 82.2% were men, 55.5% had hypertension, and 28.8% had diabetes mellitus. Patients with plaque rupture were more likely to be older, and present with a history of diabetes mellitus and reduced renal function compared with plaque erosion patients. There were no significant differences in the other clinical variables between the plaque rupture and plaque erosion groups.
We first performed a cross-sectional comparison of TMAO levels between the whole STEMI cohort and an independent set of 53 prospectively recruited individuals without known cardiovascular disease (baseline characteristics in Table II Figure 3A ). Subgroup analysis showed that plasma TMAO concentration was higher in patients with plaque rupture than in the controls (3.33 Figure 3B ).
Relationship Between Plasma TMAO Levels and Plaque Rupture
The frequency of plaque rupture increased with increasing tertiles of TMAO levels as follows: 12.5% in tertile 1 (<1.58 μM), 53.1% in tertile 2 (1.58-3.06 μM), and 91.8% in tertile 3 (3.06-17.57 μM; P<0.001). Univariate regression analysis showed that TMAO was a predictor of plaque rupture. Moreover, the significant predictive value of TMAO was preserved after adjustment for variables associated with plaque rupture in univariate analysis or reported in previous studies, including age, sex, Continuous data are presented as mean±SD or median (interquartile range), categorical variables are presented as %. CAD indicates coronary artery disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein-cholesterol; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein-cholesterol; and TMAO, trimethylamine N-oxide.
hypertension, diabetes mellitus, smoking, triglyceride, hs-CRP, and estimated glomerular filtration rate ( Table 2) .
Diagnostic Value for TMAO in Distinguishing Plaque Rupture From Plaque Erosion
ROC analysis was performed to evaluate the diagnostic value of TMAO in discriminating plaque rupture from plaque erosion. The area under the ROC was 0.89 (95% CI, 0.84-0.94; Figure 4 ). The cutoff threshold of TMAO was 1.95 μM to generate the maximum summation of sensitivity and specificity in discriminating plaque rupture from plaque erosion. The corresponding sensitivity and specificity were 88.3% and 76.8%, respectively, resulting in 82.9% of patients being correctly diagnosed. Positive and negative predictive values for TMAO at 1.95 μM were 81.0% and 85.5%, respectively. Positive and negative likelihood ratios were 3.8 and 0.15, respectively. In addition, lower cutoff values were associated with higher sensitivity and negative predictive value (Table 3) .
DISCUSSION
The present study revealed that plasma TMAO concentrations were significantly higher in patients with STEMI with plaque rupture than in those with plaque erosion as assessed by OCT. Elevated TMAO levels were found to be an independent predictor of plaque rupture, after adjustments for traditional risk factors. Moreover, ROC analysis indicated that TMAO may be a potential biomarker for distinguishing plaque rupture from plaque erosion.
Intestinal microflora play an important role in human health. 18 TMAO, a metabolite of gut microbes, is known to correlate with the pathogenesis of atherosclerosis and prognosis of CAD. [6] [7] [8] [9] [10] This study broadens the current knowledge about the role of TMAO in atherosclerosis as it shows a strongly significant and independent association between TMAO and plaque rupture in patients with STEMI. Although the precise mechanisms of association between TMAO and plaque rupture remain unclear, previous studies have provided some insights.
Inflammation and endothelial dysfunction have been demonstrated to be play an important role in the development and progression of vulnerable plaque, from lipid deposition to plaque rupture and its thrombotic complications. Dietary supplementation of TMAO or its nutritional precursors including choline and carnitine augment macrophage cholesterol accumulation and foam cell formation, 6, 7 which degrade the collagen-rich cap matrix and prompt plaque rupture. A recent study revealed that flavin-containing monooxygenase 3, primarily responsible for the production of TMAO, is a key regulator of body lipid metabolism and inflammation. 19 Moreover, several in vivo and in vitro mechanistic studies indicate that TMAO can induce vascular inflammation and endothelial dysfunction through activating the NLRP3 (nucleotide-binding oligomerization domainlike receptor family pyrin domain-containing 3) inflammasome and mitogen-activated protein kinase/nuclear factor-κB pathway, thus destabilizing plaques. [20] [21] [22] These observations suggest that TMAO might be involved in plaque rupture by promoting inflammation and endothelial dysfunction.
Interestingly, we observed similar plasma TMAO levels in the plaque erosion group and normal controls, indicating that the difference between STEMI patients and normal controls was driven by the high TMAO levels in patients with plaque rupture. The increased plasma TMAO level was associated with CAD, 7 whereas no difference was observed between the different phenotypes of CAD, such as stable CAD and acute coronary Odds ratio shown were for plasma TMAO level as a continuous variable. Model 1 adjusted for age and sex. Model 2 adjusted for all factors in model 1 plus hypertension, diabetes mellitus, smoking, and triglyceride. Model 3 adjusted for all factors in model 2 plus high-sensitivity C-reactive protein level and estimated glomerular filtration rate. TMAO indicates trimethylamine N-oxide.
syndrome. 23 The phenomenon could be elucidated by the finding of our study that high plasma TMAO levels might be merely associated with plaque rupture, thus resulting in the similar plasma TMAO levels among the CAD phenotypes.
Several previous clinical studies have reported that patients with plaque rupture had a worse prognosis than those with plaque erosion 4 ; however, the underlying mechanism remained unclear. Recent published meta-analyses demonstrated a positive dose-dependent association between plasma TMAO levels and increased cardiovascular risk and mortality. 24, 25 In our study, we found significantly elevated plasma TMAO levels in patients with plaque rupture than in those with plaque erosion, indicating that patients with plaque rupture might suffer a higher mortality than those with plaque erosion. A recent OCT-based study revealed the association between plasma TMAO levels and nonculprit plaque vulnerability in CAD patients. 23 However, the association between TMAO and the culprit plaque in patients with AMI has not been studied. Our study extends the prior findings by showing a significant association between plasma TMAO level and plaque rupture in STEMI patients.
The current guidelines for the management of STEMI generally recommend early percutaneous coronary intervention and stent implantation to achieve complete revascularization and reperfusion, regardless of the culprit lesion morphology. However, several recent studies have revealed the importance of differentiating between culprit lesion morphologies to enable customized treatment therapy to improve the prognosis of AMI, and to save substantial healthcare resources. 4, 5 OCT enables accurate in vivo diagnosis of plaque morphology 12, 13 ; however, the procedure is both invasive and expensive. Thus, finding a cost-effective and technically simple method such as a blood test to distinguish plaque morphology is crucial. Although much research has been devoted to finding biomarkers for plaque morphology, the results are conflicting. Some studies report a significant elevation in CRP and myeloperoxidase in patients with plaque rupture 26 and in plaque erosion, 27 respectively, others studies have not found any difference in the levels of CRP and myeloperoxidase between different plaque morphologies. 27, 28 Therefore, it is imperative to find a new effective biomarker to differentiate the culprit lesion morphology to improve risk stratification and clinical management of patients with STEMI.
Our study showed that plasma TMAO had the potential to serve as a peripheral biomarker for plaque rupture in patients with STEMI, with a good area under the ROC of 0.89. We found that using TMAO at a cutoff level of 1.30 μM can exclude plaque erosion with a negative likelihood ratio of 0.07 and a negative predictive value of 92.3%, indicating that TMAO <1.30 μM was effective to rule out plaque rupture. The corresponding sensitivity and specificity were 96.1% and 52.5%, respectively. The excluded patients with TMAO <1.30 μM were accurately diagnosed with plaque erosion, and pharmacological therapy rather than stent implantation might be the optimal choice in these patients. Although the diagnostic performance of TMAO is not satisfactory enough to be a stand-alone biomarker as nearly 50% of patients with plaque erosion may be misclassified as plaque rupture, it can provide information to determine the optimal treatment on account of the generally recommended stent implantation strategy in patients with STEMI. NLR indicates negative likelihood ratio; NPV, negative predictive value; PLR, positive likelihood ratio; PPV, positive predicting value; and TMAO, trimethylamine N-oxide.
*Optimal threshold value obtained from the data, which was the threshold leading to the maximum summation of sensitivity and specificity.
The importance of our study is emphasized by the modifiable nature of TMAO. As a metabolite produced by the intestinal microflora from specific dietary nutrients, changes in diets composition have a crucial effect on plasma TMAO concentrations. Subjects adhering to a vegetarian or vegan diet have decreased plasma and urine TMAO levels compared with those who are omnivorous. 6, 29 Moreover, 3,3-dimethyl-1-butanol (DMB), a structure analogue of choline, which inhibits microbial generation of trimethylamine from choline or phosphatidylcholine, has been shown to suppress plasma levels of TMAO and prevents macrophage foam cell formation and atherosclerosis development. 30 In addition, a newly developed family of mechanism-based suicide substrate inhibitors of TMA lyase, which is responsible for TMAO production, are reported to inhibit thrombosis potential without observable toxicity and increased bleeding risk. 31 Based on these studies, TMAO maybe a feasible interventional target in the primary and secondary prevention of cardiovascular disease.
Limitations
This study has several potential limitations. First, we investigated patients with STEMI who underwent OCT examination before the percutaneous coronary intervention procedure. Patients with cardiac shock, congestive heart failure, history of coronary artery bypass graft, left main diseases, extremely tortuous or heavily calcified vessels, or chronic total occlusion were not enrolled in our study. Therefore, selection bias cannot be excluded. Second, the underlying plaque morphology of the culprit lesion could have been obscured by a residual thrombus in some cases. All subjects enrolled in this study presented with STEMI resulting from thrombotic occlusion of coronary arteries. Although we excluded cases with a massive thrombus after sufficient thrombus aspiration, some ruptured plaques might have been misclassified as eroded plaques because of invisibility of the ruptured site covered by the thrombus. Third, a second independent cohort to validate the predictive value of TMAO in discriminating between plaque morphologies would significantly strengthen our results, which we aim to do in future studies. Finally, the causal relationship between plasma TMAO levels and plaque rupture remains unclear in this study; a future study should make efforts to clarify this causal association.
CONCLUSIONS
To the best of our knowledge, we demonstrated for the first time an independent association of high plasma TMAO levels with plaque rupture using OCT in patients with STEMI. TMAO has the potential to serve as a novel rule-out biomarker for plaque rupture to help improve risk stratification and management in patients with STEMI.
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